Pharma

Artificial intelligence is already reshaping workflows and productivity across all industries. The implications for value creation, however, are far from uniform. Filippos Papadopoulos, senior...

Since Stifel’s acquisition of Bryan Garnier in 2025, the US-based full-service firm has accelerated the build-out of its European platform, emerging as financial adviser...

Luca Gambini, partner, and Claudio Todisco, associate, at Portolano Cavallo - an Italy-based full-service law firm operating in complex and evolving sectors and a...

In February 2026, a group of European life sciences investors, research institutions, and ecosystem partners launched the European Life Sciences Coalition (ELSC) in association...

Authors Dr Lakshiv Dhingra, Dr Seren Marsh, Abhishek Patel and Dr Victor Chua of Mansfield Advisors consider how the GLP-1 landscape will evolve over...

The traditional approach to healthcare deal-making is undergoing a fundamental shift. As financial leverage becomes less effective and market volatility increases, operational due diligence...

After years of market turbulence, healthcare investors are cautiously eyeing 2026 as a potential turning point. But the path forward is anything but uniform....

To attract global investment and foster innovation in its life sciences sector, Britain must reshape its legal and policy frameworks, writes Clare Auty, partner...

On 25 September, hundreds of healthcare professionals, investors, and industry leaders gathered in London for McDermott Will & Schulte’s Healthcare Private Equity (HPE) Europe...

Long overlooked by mainstream investors, women’s health is finally attracting serious attention. With sustained growth, rising consumer demand, and a shift toward preventive and...